Term of Royalty Payments. Roche shall calculate and make royalty payments to Memory under this Article 5 commencing on Launch in any country. The Net Sales of a given country shall be included for purposes of calculating royalties under this Section until the later of (a) expiration of the last to expire of Composition of Matter Claim in such country and (b) ten (10) years from the Launch of such Product in such country. With respect to the ten (10) year period, the EU will be considered as one country.
Term of Royalty Payments. Roche’s obligation to make royalty payments to Pharmasset under Section 5.1 with respect to a Product shall commence on the Launch of such Product in any country of the Roche Territory. The Roche Net Sales in a given country shall be included for purposes of calculating royalties under Section 5.1 from such Launch date until the later of (a) expiration of the last to expire Valid Compound Claim of a Patent Covering such Product in such country, or (b) [***] ([***]) years from the Launch of such Product in such country.
Term of Royalty Payments. Licensee’s obligation to make royalty payments to Advaxis under Section 9.1 shall commence upon the First Commercial Sale of the first Product in any country in the Territory (the “Royalty Commencement Date”) and shall expire (the “Royalty Term”) upon the later of (i) expiration of the last to expire Valid Claim Covering a Product in the issued patents and pending patent applications listed in Schedule 1.27 and (ii) twenty (20) years from the Effective Date. Thereafter, the licenses shall be fully paid up, royalty-free and irrevocable.
Term of Royalty Payments. The duration of Rain’s royalty obligation will be determined on a country-by-country and Product-by-Product basis until the later of: (i) the loss of all Market Exclusivity for such Product in such country, (ii) the expiration of all Valid Claims of Daiichi Sankyo Patents that Cover the Licensed Compound or Product in such country, or (iii) twelve (12) years from the launch of the first Product that is sold by Rain, its Affiliate, or its Sublicensee in that country. Thereafter Rain will have a fully paid up exclusive license to the Licensed Compound and the Product(s) in that country.
Term of Royalty Payments. Royalties shall be paid on a country-by-country basis for a period often (10) years from First Commercial Sale of Product in each such country.
Term of Royalty Payments. King’s obligation to make royalty payments to Acura under this Section 9.1 shall commence twelve (12) months after the First Commercial Sale of the first Product in any country in the Territory (the “Royalty Commencement Date”) and shall expire upon the later of (i) expiration of the last to expire Valid Claim Covering a Product in such country, or (ii) fifteen (15) years from the First Commercial Sale of such Product in such country.
Term of Royalty Payments. Pharmasset’s obligation to make royalty payments to Roche under this Section 5.3 with respect to a Product shall commence on the Launch of such Product in any country of the Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets and asterisks [***], have been separately filed with the Commission.
Term of Royalty Payments. Royalties shall be paid on a country-by-country basis for a period of ten (10) years from First Commercial Sale of Product in each such country. Within thirty (30) days after the date of First Commercial Sale of Product in each country, CTI shall notify Abbott thereof in writing.
Term of Royalty Payments. Except as otherwise provided herein, Royalties shall be paid hereunder for the life of the Products.
Term of Royalty Payments. Royalty payments shall continue to accrue and be payable with respect to BMG Sales of Products and will automatically expire on a country-by-country and Product-by-Product basis as follows:
(i) for a Product which a Third Party could not manufacture, use, or sell without infringing any Geron Patent or BMG Patent, upon the expiration (or revocation) of the last to expire (or be revoked) of such Geron Patent or BMG Patent;
(ii) for a Product which a Third Party could manufacture, use, and sell without infringing any Geron Patent, [*] from its first commercial sale upon execution of this Agreement, provided, however, that the royalty on such Product shall be reduced only in the event of direct competition by a Third Party selling an equivalent product, in which case the Parties shall agree to a reduction in royalty rate, such reduced royalty rate in no event to be less than [*].
